David W. Boulton
-
- Diabetes Treatment and Management 76
- Diabetes Management and Research 25
- Pharmacology top 0.5%
- Pharmacogenetics and Drug Metabolism 19
- Pharmacology top 1%
- Pharmacogenetics and Drug Metabolism 19
- Nephrology top 2%
- Surgery top 2%
- Pancreatic function and diabetes 38
-
- Metabolism, Diabetes, and Cancer 22
-
- Drug Transport and Resistance Mechanisms 12
-
- Pharmaceutical studies and practices 10
- Pharmacological Effects and Toxicity Studies 10
- Co-authors
- Frank LaCretaC. Lindsay DeVaneSreeneeranj KasichayanulaJ. Paul FawcettSteven C. GriffenJohn S. MarkowitzPeter J. GreasleyMarc Pfister
- Journals
- SHILAP Revista de lepidopterología (1 paper)Analytical Chemistry (1 paper)Diabetes Care (2 papers)
- Partner nations
- United StatesSwedenPoland
In The Last Decade
David W. Boulton
140 papers receiving 4.8k citations
Hit Papers
Peers
Comparison fields: 5 of 129
- Endocrinology, Diabetes and Metabolism 2.6k
- Pharmacology 560
- Pharmacology 630
- Nephrology 262
- Surgery 1.4k
Countries citing papers authored by David W. Boulton
This map shows the geographic impact of David W. Boulton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David W. Boulton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David W. Boulton more than expected).
Fields of papers citing papers by David W. Boulton
This network shows the impact of papers produced by David W. Boulton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David W. Boulton. The network helps show where David W. Boulton may publish in the future.
Co-authorship network
The 25 scholars most cited alongside David W. Boulton, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 14 | |
| 3 | 2024 | 3 | |
| 4 | 2023 | 1 | |
| 5 | 2023 | 6 | |
| 6 | 2023 | 10 | |
| 7 | 2023 | 1 | |
| 8 | 2023 | 4 | |
| 9 | 2021 | 5 | |
| 10 | 2020 | 25 | |
| 11 | 2020 | 12 | |
| 12 | 2018 | 24 | |
| 13 | 2012 | 9 | |
| 14 | 2011 | 39 | |
| 15 | Pharmacokinetics of the dipeptidyl peptidase-4 inhibitor saxagliptin in subjects with renal impairment | 2009 | 7 |
| 16 | 2009 | 38 | |
| 17 | 2007 | 43 | |
| 18 | 2001 | 17 | |
| 19 | 2000 | 114 | |
| 20 | 1999 | 21 |
About David W. Boulton
David W. Boulton is a scholar working on Endocrinology, Diabetes and Metabolism, Pharmacology and Family Practice, having authored 146 papers that have together received 5.0k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (76 papers), Pancreatic function and diabetes (38 papers), Diabetes Management and Research (25 papers), Metabolism, Diabetes, and Cancer (22 papers), Pharmacogenetics and Drug Metabolism (19 papers), Drug Transport and Resistance Mechanisms (12 papers), Pharmaceutical studies and practices (10 papers) and Pharmacological Effects and Toxicity Studies (10 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (2.6k citations), Pharmacology (560 citations) and Pharmacology (630 citations). David W. Boulton has collaborated with scholars based in United States, Sweden and Poland. Frequent co-authors include Frank LaCreta, C. Lindsay DeVane, Sreeneeranj Kasichayanula, J. Paul Fawcett, Steven C. Griffen, John S. Markowitz, Peter J. Greasley, Marc Pfister, Thomas Walle and Xiaoni Liu. Their work appears in journals such as SHILAP Revista de lepidopterología, Analytical Chemistry and Diabetes Care.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.